Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7135015 | 0.80 | ALDH1A1 (0.47) | ALDH3A1ALDH1A1TP53HPGDTSHR | |
| SCHEMBL20250954 | 0.80 | HTR1A (0.48) | HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL10396554 | 0.80 | HTR1A (0.48) | HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL8762182 | 0.80 | ALDH1A1 (0.47) | ALDH3A1ALDH1A1TP53HPGDTSHR | |
| SCHEMBL10396090 | 0.80 | HTR1A (0.48) | HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL6577600 | 0.80 | ALDH1A1 (0.47) | ALDH3A1ALDH1A1TP53HPGDTSHR | |
| SCHEMBL7140484 | 0.80 | ALDH1A1 (0.47) | ALDH3A1ALDH1A1TP53HPGDTSHR | |
| SCHEMBL6579911 | 0.80 | ALDH1A1 (0.47) | ALDH3A1ALDH1A1TP53HPGDTSHR | |
| SCHEMBL7110766 | 0.80 | ALDH1A1 (0.47) | ALDH3A1ALDH1A1TP53HPGDTSHR | |
| SCHEMBL9001565 | 0.77 | ALDH1A1 (0.50) | ALDH3A1ALDH1A1TP53HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190046530-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | KONSTANTOPOULOS KONSTANTINOS (US) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190046530-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | PTGS2, PTGES2, CCAR2 | HTR1A 1364/4885DRD2 2874/4885HTR2A 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.